Welcome to our dedicated page for NGCAW news (Ticker: NGCAW), a resource for investors and traders seeking the latest updates and insights on NGCAW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NGCAW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NGCAW's position in the market.
NextGen Acquisition Corp. II has priced its initial public offering (IPO) at $10.00 per unit, totaling 35,000,000 units. The shares will trade on Nasdaq under the ticker symbol “NGCAU” starting March 23, 2021. Each unit comprises one Class A ordinary share and one-fifth of a redeemable warrant, with each warrant allowing the purchase of one Class A share at $11.50. The offering is set to close on March 25, 2021. Goldman Sachs and Credit Suisse are the joint book-running managers for this IPO, with a 45-day option for underwriters to purchase an additional 5,250,000 units.